<--- Back to Details
First PageDocument Content
Cell signaling / Programmed cell death / Cell biology / Poly ADP ribose polymerase / Lipid raft / Helicobacter pylori / Receptor / Sphingomyelin / Ceramide / Biology / Membrane biology / Lipids
Date: 2013-04-11 16:16:31
Cell signaling
Programmed cell death
Cell biology
Poly ADP ribose polymerase
Lipid raft
Helicobacter pylori
Receptor
Sphingomyelin
Ceramide
Biology
Membrane biology
Lipids

Microsoft PowerPoint - Session 5 Discussion Blanke 3 SRB HANDOUTS

Add to Reading List

Source URL: www.asmgap.org

Download Document from Source Website

File Size: 48,18 KB

Share Document on Facebook

Similar Documents

ORIGINAL ARTICLE doi:j00271.x NATURAL TRANSFORMATION INCREASES THE RATE OF ADAPTATION IN THE HUMAN PATHOGEN HELICOBACTER PYLORI

ORIGINAL ARTICLE doi:j00271.x NATURAL TRANSFORMATION INCREASES THE RATE OF ADAPTATION IN THE HUMAN PATHOGEN HELICOBACTER PYLORI

DocID: 1sDtT - View Document

Press Release  ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections Munich (Germany), October 28, 2014: ImevaX GmbH, a specialist in vaccines agai

Press Release ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections Munich (Germany), October 28, 2014: ImevaX GmbH, a specialist in vaccines agai

DocID: 1rRrC - View Document

ImmunoCard STAT!® HpSA® HD NEXT GENERATION, HIGH DEFINITION RAPID TEST FROM THE LEADER IN STOOL ANTIGEN TESTING  DEFINITIVE ANSWERS, CONFIDENT RESULTS®

ImmunoCard STAT!® HpSA® HD NEXT GENERATION, HIGH DEFINITION RAPID TEST FROM THE LEADER IN STOOL ANTIGEN TESTING DEFINITIVE ANSWERS, CONFIDENT RESULTS®

DocID: 1rtI8 - View Document

Press Release  ImevaX welcomes KfW to investor syndicate in second closing of Series A financing Munich (Germany), March 02, 2015: ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, e

Press Release ImevaX welcomes KfW to investor syndicate in second closing of Series A financing Munich (Germany), March 02, 2015: ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, e

DocID: 1rjwj - View Document

JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, GERMANY Research Centre for Infectious Diseases (ZINF) PhD STUDENT Position “Virulence factors and regulators required during infections with the food-borne pathogen Campyloba

JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, GERMANY Research Centre for Infectious Diseases (ZINF) PhD STUDENT Position “Virulence factors and regulators required during infections with the food-borne pathogen Campyloba

DocID: 1r4bs - View Document